Rashmin Bharat Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rashmin Bharat Patel has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Mrunali Rashmin Patel
Department of Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Anand, India
58 shared publications Bharat G. Patel
14 shared publicationsJolly R. Parikh
A. R. College of Pharmacy & G. H. Patel Institute of Pharmacy
6 shared publicationsKashyap K. Bhatt
B Department of Pharmceutical Chemistry & Quality Assurance , A.R. College of Pharmacy & G.H. Patel Institute of Pharmacy , Vallabh Vidynagar , Gujarat , India
6 shared publications- Richa Dave
Department of Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Anand, India
6 shared publications Ajay B. Solanki
A. R. College of Pharmacy & G. H. Patel Institute of Pharmacy, Vallabh Vidyanagar, Gujarat, India
5 shared publications
Latest Publications
- 14 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 55
Nose-to-Brain Targeted Mucoadhesive Nanoemulsion for Management of Schizophrenia: Development and Pharmacodynamic Evaluation
- 14 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 55
Nose-to-Brain Targeted Mucoadhesive Nanoemulsion for Management of Schizophrenia: Development and Pharmacodynamic Evaluation
- 29 July 2025
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 51 (11) , 1607-1623
Quantifying alpha arbutin and niacinamide from nanocosmeceutical formulation matrix: AQbD driven high-performance thin-layer chromatographic method
Background The combined therapy of alpha arbutin, a natural derivative of hydroquinone, and niacinamide is well-regarded in skincare science. It leverages the unique properties of both actives, providing a multifaceted solution to aesthetic and therapeutic skin concerns and supporting a comprehensive approach to skincare.Objective This study aimed to develop a robust HPTLC method to determine alpha arbutin and niacinamide in a nanocosmeceutical using a comprehensive approach that includes risk assessment and Analytical Quality by Design.Methods The critical method parameters influencing the HPTLC results were screened using a Plackett-Burman screening design, followed by optimization using a central composite optimization design and validation of the optimized method as per ICHQ2(R2).Results A novel HPTLC utilized pre-coated aluminum-backed HPTLC plates of Silica gel G 60 F254 using 10 µL/band injection volume, and the plate was developed using an isocratic mobile phase consisting of ethyl acetate: methanol: water (8.4:0.8:0.8%v/v/v) in a twin trough chamber pre-saturated for 30 mins with vapors of 10 mL of mobile phase. The separated components were detected at a wavelength of 273 nm. The developed HPTLC method resulted in a retardation factor of 0.31 ± 0.02 for alpha arbutin and 0.42 ± 0.02 for niacinamide, respectively. Validation results revealed the HPTLC method's specificity (peak purity ≥ 0.999), linearity (over a studied concentration range of 200-800 ng/band for alpha arbutin and 400-1600 ng/band for niacinamide), sensitivity, accuracy, precision, and robustness.Conclusion The developed robust HPTLC method was successfully implemented for the sustainable testing of the alpha arbutin and niacinamide in the nanocosmeceutical formulations.
- 29 July 2025
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 51 (11) , 1607-1623
Quantifying alpha arbutin and niacinamide from nanocosmeceutical formulation matrix: AQbD driven high-performance thin-layer chromatographic method
Background The combined therapy of alpha arbutin, a natural derivative of hydroquinone, and niacinamide is well-regarded in skincare science. It leverages the unique properties of both actives, providing a multifaceted solution to aesthetic and therapeutic skin concerns and supporting a comprehensive approach to skincare.Objective This study aimed to develop a robust HPTLC method to determine alpha arbutin and niacinamide in a nanocosmeceutical using a comprehensive approach that includes risk assessment and Analytical Quality by Design.Methods The critical method parameters influencing the HPTLC results were screened using a Plackett-Burman screening design, followed by optimization using a central composite optimization design and validation of the optimized method as per ICHQ2(R2).Results A novel HPTLC utilized pre-coated aluminum-backed HPTLC plates of Silica gel G 60 F254 using 10 µL/band injection volume, and the plate was developed using an isocratic mobile phase consisting of ethyl acetate: methanol: water (8.4:0.8:0.8%v/v/v) in a twin trough chamber pre-saturated for 30 mins with vapors of 10 mL of mobile phase. The separated components were detected at a wavelength of 273 nm. The developed HPTLC method resulted in a retardation factor of 0.31 ± 0.02 for alpha arbutin and 0.42 ± 0.02 for niacinamide, respectively. Validation results revealed the HPTLC method's specificity (peak purity ≥ 0.999), linearity (over a studied concentration range of 200-800 ng/band for alpha arbutin and 400-1600 ng/band for niacinamide), sensitivity, accuracy, precision, and robustness.Conclusion The developed robust HPTLC method was successfully implemented for the sustainable testing of the alpha arbutin and niacinamide in the nanocosmeceutical formulations.
- 27 June 2025
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (3) , 278-283
Compatibility and physicochemical stability of ceftriaxone for injection admixed with pantoprazole sodium and ondansetron hydrochloride in different infusion solutions
The study aimed to analyse the physicochemical stability and compatibility of ceftriaxone sodium (CEF) (2mg/mL) with pantoprazole sodium (PAN) (0.08mg/mL) and ondansetron hydrochloride (OND) (0.008mg/mL) in different infusion solutions, specifically 0.9% sodium chloride injection (NS) and 5% dextrose injection (5D) under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals. This study involved determining the content of CEF, PAN and OND in infusion solutions, NS and 5D under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals using high performance liquid chromatography, visual description of solution mixture, pH measurement, osmolality, particulate matter (both visible and subvisible), as well as assessing the colour and clarity of the solution (measured by absorbance at 420 nm and % transmittance at 650 nm). No significant changes were observed in pH, osmolality, particulate matter, colour and clarity of admixture in NS up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 48 hours, 25°C for 8 hours, and 37°C for 8 hours. Also, no significant changes were observed in pH and osmolality of admixture in 5D up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 4 hours, 25°C for less than 2 hours, and 37°C for less than 2 hours. This study concludes that the physicochemical stability of a ternary admixture containing CEF, PAN and OND is diluent and temperature dependent. NS ensures acceptable stability, whereas 5D causes rapid degradation. For safety and efficacy, NS is recommended, with refrigerated storage preferred. Based on physicochemical stability data, the use of this parenteral admixture with 5D is not recommended.
- 27 June 2025
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (3) , 278-283
Compatibility and physicochemical stability of ceftriaxone for injection admixed with pantoprazole sodium and ondansetron hydrochloride in different infusion solutions
The study aimed to analyse the physicochemical stability and compatibility of ceftriaxone sodium (CEF) (2mg/mL) with pantoprazole sodium (PAN) (0.08mg/mL) and ondansetron hydrochloride (OND) (0.008mg/mL) in different infusion solutions, specifically 0.9% sodium chloride injection (NS) and 5% dextrose injection (5D) under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals. This study involved determining the content of CEF, PAN and OND in infusion solutions, NS and 5D under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals using high performance liquid chromatography, visual description of solution mixture, pH measurement, osmolality, particulate matter (both visible and subvisible), as well as assessing the colour and clarity of the solution (measured by absorbance at 420 nm and % transmittance at 650 nm). No significant changes were observed in pH, osmolality, particulate matter, colour and clarity of admixture in NS up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 48 hours, 25°C for 8 hours, and 37°C for 8 hours. Also, no significant changes were observed in pH and osmolality of admixture in 5D up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 4 hours, 25°C for less than 2 hours, and 37°C for less than 2 hours. This study concludes that the physicochemical stability of a ternary admixture containing CEF, PAN and OND is diluent and temperature dependent. NS ensures acceptable stability, whereas 5D causes rapid degradation. For safety and efficacy, NS is recommended, with refrigerated storage preferred. Based on physicochemical stability data, the use of this parenteral admixture with 5D is not recommended.
- 7 June 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (6)
MS‐Compatible HPLC Method for Simultaneous Estimation of Ceftriaxone, Pantoprazole, and Ondansetron in Parenteral Formulations and Admixtures
Concomitant therapies are used for the treatment of serious infection in hospitalized patients. In such treatment, antibiotics had been co‐administered with other drugs like antacids and antiemetic drugs admixed in infusion solution. Such a combination is ceftriaxone sodium, pantoprazole sodium, and ondansetron hydrochloride in parenteral admixture with 5% w/v dextrose injection and 0.9% w/v sodium chloride injection. For evaluation of such a type of combination, a robust mass spectroscopy‐compatible HPLC method for simultaneous quantification had been developed with the aid of Analytical Quality by Design , and the method operable domain region and by evaluating the interaction between critical method parameters/critical method attributes by optimizing the HPLC method using the Box–Behnken design. The optimized method was achieved using a Tragetsil RP‐18 (150 mm × 4.6 mm, 3 µm) column, a gradient of buffer (0.1% trifluoroacetic acid in water), and a solvent mixer (methanol:acetonitrile (50:50, %v/v)) at flow rate of 1 mL/min and detection wavelength at 220 nm. The proposed method was successfully validated according to International Council for Harmonization Q2(R2) guidelines for specificity, accuracy, precision, sensitivity, and linearity over concentrations ranging 100–300 µg/mL for ceftriaxone sodium, 4–12 µg/mL for pantoprazole sodium, 0.4–1.2 µg/mL for ondansetron hydrochloride, respectively. The method exhibits a high degree of accuracy, which was found to be between 98.3% and 101.5% for triplicate at three concentrations. Alongside, limit of quantification level is achieved at 4.01, 0.16, and 0.20 µg/mL for ceftriaxone, pantoprazole, and ondansetron respectively. Analytical Quality by Design based method was successfully applied to estimate ceftriaxone sodium, pantoprazole sodium, and ondansetron hydrochloride in their marketed formulations, such as Monocef, Pantodac, and Emeset respectively as well as in parenteral admixture with 5% w/v dextrose injection and 0.9% w/v sodium chloride injection.
- 7 June 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (6)
MS‐Compatible HPLC Method for Simultaneous Estimation of Ceftriaxone, Pantoprazole, and Ondansetron in Parenteral Formulations and Admixtures
Concomitant therapies are used for the treatment of serious infection in hospitalized patients. In such treatment, antibiotics had been co‐administered with other drugs like antacids and antiemetic drugs admixed in infusion solution. Such a combination is ceftriaxone sodium, pantoprazole sodium, and ondansetron hydrochloride in parenteral admixture with 5% w/v dextrose injection and 0.9% w/v sodium chloride injection. For evaluation of such a type of combination, a robust mass spectroscopy‐compatible HPLC method for simultaneous quantification had been developed with the aid of Analytical Quality by Design , and the method operable domain region and by evaluating the interaction between critical method parameters/critical method attributes by optimizing the HPLC method using the Box–Behnken design. The optimized method was achieved using a Tragetsil RP‐18 (150 mm × 4.6 mm, 3 µm) column, a gradient of buffer (0.1% trifluoroacetic acid in water), and a solvent mixer (methanol:acetonitrile (50:50, %v/v)) at flow rate of 1 mL/min and detection wavelength at 220 nm. The proposed method was successfully validated according to International Council for Harmonization Q2(R2) guidelines for specificity, accuracy, precision, sensitivity, and linearity over concentrations ranging 100–300 µg/mL for ceftriaxone sodium, 4–12 µg/mL for pantoprazole sodium, 0.4–1.2 µg/mL for ondansetron hydrochloride, respectively. The method exhibits a high degree of accuracy, which was found to be between 98.3% and 101.5% for triplicate at three concentrations. Alongside, limit of quantification level is achieved at 4.01, 0.16, and 0.20 µg/mL for ceftriaxone, pantoprazole, and ondansetron respectively. Analytical Quality by Design based method was successfully applied to estimate ceftriaxone sodium, pantoprazole sodium, and ondansetron hydrochloride in their marketed formulations, such as Monocef, Pantodac, and Emeset respectively as well as in parenteral admixture with 5% w/v dextrose injection and 0.9% w/v sodium chloride injection.
- 27 January 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 105
Unlocking the potential of novel hybrid lipid polymer nanoparticles in redefining camptothecin delivery: Achieving controlled release, enhanced cytotoxicity, and improved pharmacokinetics for colorectal cancer therapy
- 27 January 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 105
Unlocking the potential of novel hybrid lipid polymer nanoparticles in redefining camptothecin delivery: Achieving controlled release, enhanced cytotoxicity, and improved pharmacokinetics for colorectal cancer therapy
- 6 January 2025
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 51 (2) , 111-122
AQbD integrated high-performance thin layer chromatographic method for quantitative estimation of Tavaborole in the presence of its degradants and the matrix of nanostructured lipid carriers
Tavaborole (TAV), a benzoxaborole derivative, is an FDA-approved antifungal agent for treating onychomycosis, a common and persistent fungal infection of the toenails. This study aimed to develop a robust stability-indicating HPTLC method to determine TAV in nanostructured lipid carriers (NLC) using a comprehensive approach that includes risk assessment, and Analytical Quality by Design. The critical method parameters influencing the HPTLC results were screened using a Placket-Burman screening design followed by its optimization using a central composite optimization design. The developed method was validated as per ICH recommendation. Optimized method utilized pre-coated aluminum-backed HPTLC plates using 10 µL/band injection volume, and the plate was developed using an isocratic mobile phase consisting of toluene: ethyl acetate: formic acid (75:25:1%v/v/v) in twin trough chamber pre-saturated for 20 mins with vapors of 10 mL of mobile phase. The separated components were detected at a wavelength of 221 nm. The developed HPTLC method resulted in a retardation factor of 0.49 ± 0.04 for TAV. Validation results revealed the HPTLC method's specificity (peak purity ≥ 0.999), linearity over a concentration range of 2-10 μg/band, sensitivity (LOD 0.209 μg and LOQ 0.635 μg), accuracy (99.68 - 101.43%w/w), and precision (%RSD < 2.0). The developed robust stability-indicating HPTLC method was successfully implemented for the sustainable testing of the TAV in the NLC formulations and stability testing.
- 6 January 2025
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 51 (2) , 111-122
AQbD integrated high-performance thin layer chromatographic method for quantitative estimation of Tavaborole in the presence of its degradants and the matrix of nanostructured lipid carriers
Tavaborole (TAV), a benzoxaborole derivative, is an FDA-approved antifungal agent for treating onychomycosis, a common and persistent fungal infection of the toenails. This study aimed to develop a robust stability-indicating HPTLC method to determine TAV in nanostructured lipid carriers (NLC) using a comprehensive approach that includes risk assessment, and Analytical Quality by Design. The critical method parameters influencing the HPTLC results were screened using a Placket-Burman screening design followed by its optimization using a central composite optimization design. The developed method was validated as per ICH recommendation. Optimized method utilized pre-coated aluminum-backed HPTLC plates using 10 µL/band injection volume, and the plate was developed using an isocratic mobile phase consisting of toluene: ethyl acetate: formic acid (75:25:1%v/v/v) in twin trough chamber pre-saturated for 20 mins with vapors of 10 mL of mobile phase. The separated components were detected at a wavelength of 221 nm. The developed HPTLC method resulted in a retardation factor of 0.49 ± 0.04 for TAV. Validation results revealed the HPTLC method's specificity (peak purity ≥ 0.999), linearity over a concentration range of 2-10 μg/band, sensitivity (LOD 0.209 μg and LOQ 0.635 μg), accuracy (99.68 - 101.43%w/w), and precision (%RSD < 2.0). The developed robust stability-indicating HPTLC method was successfully implemented for the sustainable testing of the TAV in the NLC formulations and stability testing.
- 27 December 2024
- Published by Wiley in Separation Science Plus
- Vol. 8 (1)
Analytical Quality by Design Based HPLC for Quantitative Analysis of Teneligliptin and Rosuvastatin Calcium Tablets in the Presence of Force Degradation Products
The application of analytical quality by design in developing an HPLC method ensures robust, reliable, and regulatory‐compliant pharmaceutical analysis. This study aimed to establish a stability‐indicating HPLC for the quantification of teneligliptin and rosuvastatin calcium in tablets using analytical quality by design principles. The analytical target profile was defined, and a risk assessment identified critical method attributes and critical method parameters. A Plackett–Burman design screened significant critical method parameters, followed by optimization using a central composite design. The optimized method utilized a Phenomenex Gemini C18 column with a mobile phase of phosphate buffer (pH 5.0) and ACN (64:36% v/v), achieving retention times of 4.27 ± 0.2 min for teneligliptin and 11.84 ± 0.2 min for rosuvastatin. The HPLC method was validated as per International Council for Harmonisation (ICH) guidelines, demonstrating good linearity across concentration ranges of 20–60 µg/mL of teneligliptin and 10–30 µg/mL of rosuvastatin, respectively. Forced degradation studies under various stress conditions confirmed the method's specificity, ensuring reliable detection of teneligliptin and rosuvastatin even in the presence of degradation products. This study offers an innovative and efficient solution for the analysis of teneligliptin and rosuvastatin in combined fixed‐dose tablet formulations.
- 27 December 2024
- Published by Wiley in Separation Science Plus
- Vol. 8 (1)
Analytical Quality by Design Based HPLC for Quantitative Analysis of Teneligliptin and Rosuvastatin Calcium Tablets in the Presence of Force Degradation Products
The application of analytical quality by design in developing an HPLC method ensures robust, reliable, and regulatory‐compliant pharmaceutical analysis. This study aimed to establish a stability‐indicating HPLC for the quantification of teneligliptin and rosuvastatin calcium in tablets using analytical quality by design principles. The analytical target profile was defined, and a risk assessment identified critical method attributes and critical method parameters. A Plackett–Burman design screened significant critical method parameters, followed by optimization using a central composite design. The optimized method utilized a Phenomenex Gemini C18 column with a mobile phase of phosphate buffer (pH 5.0) and ACN (64:36% v/v), achieving retention times of 4.27 ± 0.2 min for teneligliptin and 11.84 ± 0.2 min for rosuvastatin. The HPLC method was validated as per International Council for Harmonisation (ICH) guidelines, demonstrating good linearity across concentration ranges of 20–60 µg/mL of teneligliptin and 10–30 µg/mL of rosuvastatin, respectively. Forced degradation studies under various stress conditions confirmed the method's specificity, ensuring reliable detection of teneligliptin and rosuvastatin even in the presence of degradation products. This study offers an innovative and efficient solution for the analysis of teneligliptin and rosuvastatin in combined fixed‐dose tablet formulations.
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Drug Delivery Letters
- Vol. 14 (2) , 135-150
Revolutionizing Nitrofurantoin Delivery: Unraveling Challenges and Pioneering Solutions for Enhanced Efficacy in UTI Treatment
Nitrofurantoin is an antimicrobial drug, highly effective in the treatment of critical or chronic bacterial infections of the urinary tract, and hence, it is the first line choice of drug for the treatment of urinary tract infections (UTI). Although the molecule is legacy in nature, there are many challenges in terms of drug product formulation and efficacy thereof. The authors are main-ly focused in this literature review on, but not limited to, understanding the molecule in terms of physico-chemical properties of the drug, pharmacokinetics and pharmacodynamics, approved and withdrawn formulations, challenges concerning drug formulation, the cause of drug shortage in the market, improvement areas in terms of formulation and its therapeutic effectiveness. The au-thors found during their widespread review that the major challenge in the existing conventional drug delivery system of nitrofurantoin is the fluctuation of plasma concentration owing to its var-iability in drug absorption. Further, they understood that the variability in absorption is due to in-herent variability in particle size distribution. Based on the findings, authors also explored the possibilities to deliver the drug in novel drug delivery systems such as nano self-emulsifying emulsions, nanoemulsions and multiple emulsions where the drug can be presented in soluble form and hence the variability in absorption and fluctuation in plasma concentration of drug can be avoided and described briefly the salient features of each drug delivery in this review.
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Drug Delivery Letters
- Vol. 14 (2) , 135-150
Revolutionizing Nitrofurantoin Delivery: Unraveling Challenges and Pioneering Solutions for Enhanced Efficacy in UTI Treatment
Nitrofurantoin is an antimicrobial drug, highly effective in the treatment of critical or chronic bacterial infections of the urinary tract, and hence, it is the first line choice of drug for the treatment of urinary tract infections (UTI). Although the molecule is legacy in nature, there are many challenges in terms of drug product formulation and efficacy thereof. The authors are main-ly focused in this literature review on, but not limited to, understanding the molecule in terms of physico-chemical properties of the drug, pharmacokinetics and pharmacodynamics, approved and withdrawn formulations, challenges concerning drug formulation, the cause of drug shortage in the market, improvement areas in terms of formulation and its therapeutic effectiveness. The au-thors found during their widespread review that the major challenge in the existing conventional drug delivery system of nitrofurantoin is the fluctuation of plasma concentration owing to its var-iability in drug absorption. Further, they understood that the variability in absorption is due to in-herent variability in particle size distribution. Based on the findings, authors also explored the possibilities to deliver the drug in novel drug delivery systems such as nano self-emulsifying emulsions, nanoemulsions and multiple emulsions where the drug can be presented in soluble form and hence the variability in absorption and fluctuation in plasma concentration of drug can be avoided and described briefly the salient features of each drug delivery in this review.